Kiora Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.5022
- Today's High:
- $0.539
- Open Price:
- $0.528
- 52W Low:
- $0.462
- 52W High:
- $10.39
- Prev. Close:
- $0.51
- Volume:
- 42106
Company Statistics
- Market Cap.:
- $3.53 million
- Book Value:
- 1.974
- Revenue TTM:
- $12059
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-5137983
- Profit Margin:
- 0%
- Return on Assets TTM:
- -39.54%
- Return on Equity TTM:
- -108.02%
Company Profile
Kiora Pharmaceuticals Inc had its IPO on 2015-07-31 under the ticker symbol KPRX.
The company operates in the Healthcare sector and Biotechnology industry. Kiora Pharmaceuticals Inc has a staff strength of 12 employees.
Stock update
Shares of Kiora Pharmaceuticals Inc opened at $0.53 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.5 - $0.54, and closed at $0.54.
This is a +5.69% increase from the previous day's closing price.
A total volume of 42,106 shares were traded at the close of the day’s session.
In the last one week, shares of Kiora Pharmaceuticals Inc have increased by +10.45%.
Kiora Pharmaceuticals Inc's Key Ratios
Kiora Pharmaceuticals Inc has a market cap of $3.53 million, indicating a price to book ratio of 0.3451 and a price to sales ratio of 535.5867.
In the last 12-months Kiora Pharmaceuticals Inc’s revenue was $12059 with a gross profit of $-5137983 and an EBITDA of $-11129118. The EBITDA ratio measures Kiora Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kiora Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -39.54% with a return of equity of -108.02%.
In Q2, Kiora Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kiora Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.96 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kiora Pharmaceuticals Inc’s profitability.
Kiora Pharmaceuticals Inc stock is trading at a EV to sales ratio of 569.4141 and a EV to EBITDA ratio of 0.0628. Its price to sales ratio in the trailing 12-months stood at 535.5867.
Kiora Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $19.88 million
- Total Liabilities
- $1.88 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Kiora Pharmaceuticals Inc ended 2024 with $19.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.88 million while shareholder equity stood at $13.64 million.
Kiora Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $1.88 million in other current liabilities, 69129.00 in common stock, $-138945308.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.95 million and cash and short-term investments were $7.95 million. The company’s total short-term debt was $39,009 while long-term debt stood at $0.
Kiora Pharmaceuticals Inc’s total current assets stands at $9.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $804511.00 compared to accounts payable of $131319.00 and inventory worth $198659.00.
In 2024, Kiora Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Kiora Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.54
- 52-Week High
- $10.39
- 52-Week Low
- $0.462
- Analyst Target Price
- $46
Kiora Pharmaceuticals Inc stock is currently trading at $0.54 per share. It touched a 52-week high of $10.39 and a 52-week low of $10.39. Analysts tracking the stock have a 12-month average target price of $46.
Its 50-day moving average was $0.57 and 200-day moving average was $2.57 The short ratio stood at 0.67 indicating a short percent outstanding of 0%.
Around 638.2% of the company’s stock are held by insiders while 369.9% are held by institutions.
Frequently Asked Questions About Kiora Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.